{
    "patient_id": "MDT2024001",
    "summary": "62-year-old female with newly diagnosed stage IIIA KRAS G12C mutated lung adenocarcinoma with high PD-L1 expression.",
    "ehr_analysis": {
        "key_history_points": [
            "Former smoker, quit 10 years ago",
            "Type 2 Diabetes - well controlled on Metformin",
            "Hypertension - well controlled on Lisinopril",
            "Osteoarthritis"
        ],
        "current_presentation": {
            "main_symptoms": [
                "Persistent cough with hemoptysis",
                "Weight loss of 5kg in 3 months",
                "Constitutional symptoms present"
            ],
            "performance_status": "ECOG 1",
            "comorbidity_impact": "Well-controlled comorbidities, suitable for aggressive therapy"
        }
    },
    "imaging_analysis": {
        "disease_extent": {
            "primary_tumor": "3.8 cm RUL mass, SUV 12.4",
            "nodal_status": "Multiple FDG-avid hilar and mediastinal nodes",
            "metastatic_status": "No distant metastases"
        },
        "staging": {
            "clinical_stage": "cT2aN2M0, Stage IIIA",
            "key_findings": [
                "Spiculated RUL mass",
                "Hilar and mediastinal lymphadenopathy",
                "No distant disease on PET-CT"
            ]
        }
    },
    "pathology_analysis": {
        "histology": "Adenocarcinoma",
        "molecular_profile": {
            "key_mutations": "KRAS G12C mutation",
            "immunotherapy_markers": "PD-L1 80%",
            "other_markers": {
                "EGFR": "Wild type",
                "ALK": "Negative",
                "ROS1": "Negative"
            }
        },
        "implications": "Potentially eligible for KRAS G12C inhibitors and immunotherapy"
    },
    "guideline_recommendations": [
        {
            "guideline": "NCCN Non-Small Cell Lung Cancer",
            "version": "2024.1",
            "category": "Stage IIIA Treatment",
            "recommendations": [
                "Consider concurrent chemoradiation followed by immunotherapy",
                "Clinical trial participation if available",
                "Consider surgical evaluation for potential resection"
            ]
        }
    ],
    "specialist_assessment": {
        "overall_assessment": "Potentially curable stage IIIA NSCLC with favorable molecular profile",
        "treatment_considerations": [
            "High PD-L1 expression favors immunotherapy inclusion",
            "KRAS G12C mutation offers additional targeted therapy options",
            "Good performance status allows aggressive approach"
        ],
        "proposed_approach": "Multi-modality therapy with curative intent"
    },
    "treatment_options": [
        {
            "option": "Concurrent Chemoradiation + Immunotherapy",
            "details": {
                "sequence": [
                    "Concurrent platinum-based chemotherapy with radiation",
                    "Followed by consolidation durvalumab"
                ],
                "evidence_level": "Category 1",
                "pros": [
                    "Standard of care for stage IIIA",
                    "Curative intent",
                    "Strong evidence base"
                ],
                "cons": [
                    "Treatment toxicity",
                    "Duration of therapy"
                ]
            }
        },
        {
            "option": "Clinical Trial",
            "details": {
                "description": "Novel combinations with KRAS G12C inhibitors",
                "evidence_level": "Investigational",
                "pros": [
                    "Access to novel therapies",
                    "High PD-L1 and KRAS G12C make good candidate"
                ],
                "cons": [
                    "Availability uncertain",
                    "Unknown efficacy"
                ]
            }
        }
    ],
    "evaluation_score": 0.95,
    "evaluation_comments": "Comprehensive assessment with evidence-based recommendations. All relevant molecular and clinical factors considered. Clear treatment prioritization provided."
} 